Buscopan vs Glucagon: In-depth Analysis of Technical Pros and Cons
Abstract: This analysis compares glucagon (a peptide hormone) and Buscopan (hyoscine butylbromide) for gastrointestinal spasmolysis. Glucagon offers superior efficacy in severe cases with minimal anticholinergic side effects but requires cold-chain logistics and prescription certification. Buscopan, a synthetic alkaloid, provides cost-effective, room-temperature stability and broader OTC accessibility. Market trends show rising demand for peptide-based therapies, yet glucagon’s high cost and limited factory GMP certifications hinder adoption. Buscopan dominates first-line use due to established brand trust and simpler regulatory compliance. Technical pros: glucagon’s targeted receptor action vs. Buscopan’s rapid onset. Cons: glucagon’s short half-life and storage constraints. Selection criteria prioritize indication severity, logistics capability, and product certification status.